European Journal of Cancer
Volume 41, Issue 18 , Pages 2861-2867 , December 2005

Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: A phase I study

  • Eric François

      Affiliations

    • Department of Medical Oncology, Gastroenterology Unit, Centre Antoine-Lacassagne, Avenue de Valombrose, 06189 Nice, Cedex 2, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 492 03 11 14; fax: +33 492 03 15 46.
    • ,
  • Marc Ychou

      Affiliations

    • Centre Val d’Aurelle, Montpellier, France
    • ,
  • Michel Ducreux

      Affiliations

    • Centre Gustave-Roussy, Villejuif, France
    • ,
  • Frédérique Bertheault-Cvitkovic

      Affiliations

    • Centre René Huguenin, St. Cloud, France
    • ,
  • Marc Giovannini

      Affiliations

    • Centre Paoli-Calmettes, Marseille, France
    • ,
  • Thierry Conroy

      Affiliations

    • Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France
    • ,
  • Claire Lemanski

      Affiliations

    • Centre Val d’Aurelle, Montpellier, France
    • ,
  • Olivier Thomas

      Affiliations

    • Department of Medical Oncology, Gastroenterology Unit, Centre Antoine-Lacassagne, Avenue de Valombrose, 06189 Nice, Cedex 2, France
    • ,
  • Valérie Magnin

      Affiliations

    • Centre Paoli-Calmettes, Marseille, France
    • ,
  • Groupe Digestif de la Fédération Nationale des Centres de Lutte Contre le Cancer

Received 22 June 2005 ,Revised 17 August 2005 ,Accepted 18 August 2005.

References 

  1. Swedish Rectal Cancer Trial . Improved survival with preoperative radiotherapy in respectable rectal cancer. New Engl J Med. 1997;336:980–987
  2. Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: a metanalysis. JAMA. 2000;284:1008–1015
  3. Kapiteijn E, Marijen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–646
  4. François Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and the rate of sphinctersparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17:2396–2402
  5. Meade P, Blatchford G, Thorson A, et al. Preoperative chemoradiation downstages locally advanced ultrasound-staged rectal cancer. Am J Surg. 1995;170:609–613
  6. Myerson R, Valentini V, Birnbaum E, et al. A phase I/II trial of threedimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma. Int J Radiat Oncol Biol Phys. 2001;50:1299–1308
  7. O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. New Engl J Med. 1994;331:502–507
  8. Smalley S, Benedetti J, Williamson S, et al. Intergroup 0144-phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs. prolonged venous infusion (PVI) before and after XRT+PVI vs. bolus 5-FU+leucovorin (LV)+levamisole before and after XRT+bolus 5FU+LV. Proc Am Soc Clin Oncol. 2003;22:251
  9. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative radiochemotherapy for rectal cancer. New Engl J Med. 2004;351:1731–1740
  10. Gerard JP, Bonnetain F, Conroy T, et al. Preoperative radiotherapy ±5FU/folinic acid in T3-4 rectal cancers: results of the FFCD 9203 randomized trial. J Clin Oncol. 2005;23:247s
  11. Bosset JF, Calais G, Mineur L, et al. Preoperative radiotherapy in rectal cancer: effect and timing of additional chemotherapy. 5-year results of the EORTC 22921 trial. J Clin Oncol. 2005;23:247s
  12. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808–815
  13. Saltz LB, Cox JV, Blanke C, et al. Irinotecan study group: irinotecan plus fluorouracil and leucovorinfor metastatic colorectal cancer. New Engl J Med. 2000;343:905–914
  14. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet. 2000;355:1041–1047
  15. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947
  16. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulate fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–147
  17. Golberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30
  18. Magné N, Fischel JL, Formento P, et al. Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. Oncology. 2003;64:280–287
  19. Cividalli A, Ceciarelli F, Livdi E, et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys. 2002;52:1092–1098
  20. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002;20:2844–2850
  21. Aschele C, Friso M, Pucciarelli S, et al. A phase I–II study of weekly oxaliplatin (OXA), 5-fluorouracil (FU) continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol. 2002;21:133
  22. Caussanel JP, Lévi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulate rate compared with constant rate. J Natl Cancer Inst. 1990;82:1046–1050
  23. Carraro S, Roca EL, Cartelli C, et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3–T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys. 2002;54:397–402
  24. Sebag-Montefiore D, Glynne-Jones R, Falk S, et al. Preoperative radiation and oxaliplatin in combination with 5-fluorouracil and low-dose leucovorin in locally advanced rectal cancer. Proc Am Soc Clin Oncol. 2002;21:140
  25. Freyer G, Bossard N, Romestaing P, et al. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol. 2001;19:2433–2438
  26. Minsky B, Cohen A, Enker W, et al. Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. Cancer. 1994;73:273–278
  27. Marsh R, Chu N-M, Vauthey J-N, et al. Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Cancer. 1996;78:217–225
  28. Gerard JP, Chapet O, Nemoz C, et al. Concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol. 2003;21:1119–1124
  29. Kouloulias V. Quality assurance in radiotherapy. Eur J Cancer. 2003;39:415–422
  30. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5:2948–2953
  31. Rödel C, Grabenbauer G, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin and radiation for rectal cancer. J Clin Oncol. 2003;21:3098–3104
  32. Honhon B, Duck L, Coster B, et al. A phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma: the RadiOxCape study. Eur J Cancer. 2003;1(Suppl.):S80;[abstract 260]
  33. Andre T, Figer A, Cervantes A, et al. FOLFOX 7 compared to FOLFOX4. Preliminary results of the randomized optimox study. Proc Am Soc Clin Oncol. 2003;22:253

PII: S0959-8049(05)00839-7

doi: 10.1016/j.ejca.2005.08.029

European Journal of Cancer
Volume 41, Issue 18 , Pages 2861-2867 , December 2005

Article Tools